J9317 HCPCS code: Injection, sacituzumab govitecan-hziy, 2.5 mg
J9317 is the HCPCS Level II code for injection, sacituzumab govitecan-hziy, 2.5 mg. In 2024 Medicare paid an average of $26.64 per service for J9317 across 2,810,827 services. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case. The NCCI unit limit is 648 per day on outpatient hospital claims. Medicare volume rose 37% from 2022 to 2024 (2,046,262 to 2,810,827 services). In 2024, about 1,634 clinicians billed Medicare for J9317 for 1,161 beneficiaries; California, Florida, Texas accounted for 38% of services.
Code details
| Field | Value |
|---|---|
| Section | J codes — Drugs administered other than oral method |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1D — Chemotherapy |
| Added | 2021-01-01 |
| Last action effective | 2021-01-01 |
Who bills J9317 (2024)
| Measure | Value |
|---|---|
| Clinicians billing (by place of service) | 1,634 |
| Medicare beneficiaries | 1,161 |
| States with claims | 30 |
| Share of services in top 3 states (California, Florida, Texas) | 38% |
Counts only. Supplier and clinician names, contact lists and state-by-state detail are in Caduvo.
Medicare utilization for J9317, 2022–2024
| Year | Services | Beneficiaries | Avg. allowed | Avg. paid |
|---|---|---|---|---|
| 2022 | 2,046,262 | 851 | $30.88 | $24.66 |
| 2023 | 2,739,562 | 1,157 | $32.12 | $25.59 |
| 2024 | 2,810,827 | 1,161 | $33.43 | $26.64 |
States with the most J9317 services (2024)
| State | Services | Avg. paid |
|---|---|---|
| California | 374,217 | $26.70 |
| Florida | 319,143 | $26.82 |
| Texas | 306,714 | $26.10 |
| Illinois | 150,458 | $26.97 |
| Maryland | 135,556 | $26.30 |
NCCI unit limits (MUE)
| Claim type | Max units per day | Rationale |
|---|---|---|
| outpatient hospital claims | 648 | CMS Policy |
| practitioner claims | 648 | CMS Policy |
What changed for J9317
- 2021-01-01: J9317 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code J9317?
J9317 is the HCPCS Level II code for injection, sacituzumab govitecan-hziy, 2.5 mg. Short descriptor: "Sacituzumab govitecan-hziy".
How much does Medicare pay for J9317?
In 2024, the average Medicare payment was $26.64 per service (average allowed $33.43).
Does Medicare cover J9317?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
How many units of J9317 can be billed per day?
648 on outpatient hospital claims; 648 on practitioner claims (NCCI medically unlikely edits).
Related J93 codes
- J9300 — Injection, gemtuzumab ozogamicin, 5 mg
- J9301 — Injection, obinutuzumab, 10 mg
- J9302 — Injection, ofatumumab, 10 mg
- J9303 — Injection, panitumumab, 10 mg
- J9304 — Injection, pemetrexed (pemfexy), 10 mg
- J9305 — Injection, pemetrexed, not otherwise specified, 10 mg
- J9306 — Injection, pertuzumab, 1 mg
- J9307 — Injection, pralatrexate, 1 mg
- J9308 — Injection, ramucirumab, 5 mg
- J9309 — Injection, polatuzumab vedotin-piiq, 1 mg
- J9310 — Injection, rituximab, 100 mg
- J9311 — Injection, rituximab 10 mg and hyaluronidase
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under J9317
- Watch J9317 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for J9317
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.